リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Case-control study of postprocedural arterial puncture site hemorrhage after neuroendovascular treatment」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Case-control study of postprocedural arterial puncture site hemorrhage after neuroendovascular treatment

Tamari, Yosuke Izumi, Takashi Nishihori, Masahiro Imai, Tasuku Ito, Masashi Tsukada, Tetsuya Ishida, Mamoru Wakabayashi, Toshihiko 名古屋大学

2021.02

概要

Puncture site hemorrhage following femoral artery catheterization is a significant cause of morbidity. The aim of this case-control study was to identify predictors of postprocedural arterial hemorrhage at the puncture site. We retrospectively reviewed 255 patients who underwent endovascular treatment at our institution over a 23-month period and classified them into a hemorrhage group and a non-hemorrhage group. Puncture site hemorrhage occurred in 15 patients (5.9%). Clinical factors associated with a sig-nificantly increased risk of puncture site bleeding included patients whose postoperative activated clotting time of ≥300 seconds before removal of the sheath (9 patients, 11.8%; P<0.05), those who received triple antiplatelet therapy (n=4, 17.4%; P<0.05) and the group administered heparin postoperatively (7 patients, 13.2%; P<0.05). The effects of low on-treatment platelet reactivity, i.e., P2Y12 reaction units <95%, sheath size, hemostasis method used, and operating time were not clinically significant. Our findings suggest an increased risk of puncture site hemorrhage in patients who either had an activated clotting time ≥300 seconds before the postoperative removal of the sheath, had received triple antiplatelet therapy, or were administered heparin postoperatively.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

1 Sato M, Matsumaru Y, Sakai N, Yoshimura S, JR-NET Study Group Affiliations. Detailed analysis of puncture site vascular complications in Japanese Registry of Neuroendovascular Therapy (JR-NET) and JR-NET2. Neurol Med Chir (Tokyo). 2014;54 Suppl 2:17–22.

2 Upponi SS, Ganeshan AG, Warakaulle DR, Phillips-Hughes J, Boardman P, Uberoi R. Angioseal versus manual compression for haemostasis following peripheral vascular diagnostic and interventional procedures--a randomized controlled trial. Eur J Radiol. 2007;61(2):332–334. doi:10.1016/j.ejrad.2006.09.007.

3 Starnes BW, O’Donnell SD, Gillespie DL, et al. Percutaneous arterial closure in peripheral vascular disease: a prospective randomized evaluation of the Perclose device. J Vasc Surg. 2003;38(2):263–271. doi:10.1016/ s0741-5214(03)00291-x.

4 Wong SC, Bachinsky W, Cambier P, et al. A randomized comparison of a novel bioabsorbable vascular closure device versus manual compression in the achievement of hemostasis after percutaneous femoral procedures the ECLPISE (Ensure’s Vascular Closure Device Speeds Hemostasis Trial). JACC Cardiovasc Interv. 2009;2(8):785–793. doi:10.1016/j.jcin.2009.06.006.

5 Das R, Ahmed K, Athanasiou T, Morgan RA, Belli AM. Arterial closure devices versus manual compression for femoral haemostasis in interventional radiological procedures: a systematic review and meta-analysis. Cardiovasc Intervent Radiol. 2011;34(4):723–738. doi:10.1007/s00270-010-9981-0.

6 Koreny M, Riedmüller E, Nikfardjam M, Siostrzonek P, Müllner M. Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: systematic review and meta- analysis. JAMA. 2004;291(3):350–357. doi:10.1001/jama.291.3.350.

7 Moscucci M, Fox KAA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2003;24(20):1815–1823. doi:10.1016/ s0195-668x(03)00485-8.

8 Berkowitz SD, Stinnett S, Cohen M, Fromell GJ, Bigonzi F, ESSENCE Investigators. Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. Am J Cardiol. 2001;88(11):1230–1234. doi:10.1016/s0002-9149(01)02082-3.

9 Sinnaeve PR, Alexander JH, Bogaerts K, et al. Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. Am Heart J. 2004;147(6):993–998. doi:10.1016/j.ahj.2003.12.028.

10 McKevitt FM, Randall MS, Cleveland TJ, Gaines PA, Tan KT, Venables GS. The benefits of combined anti- platelet treatment in carotid artery stenting. Eur J Vasc Endovasc Surg. 2005;29(5):522–527. doi:10.1016/j. ejvs.2005.01.012.

11 Dalainas I, Nano G, Bianchi P, Stegher S, Malacrida G, Tealdi DG. Dual antiplatelet regime versus acetyl-acetic acid for carotid artery stenting. Cardiovasc Intervent Radiol. 2006;29(4):519–521. doi:10.1007/ s00270-005-5288-y.

12 Nishikawa Y, Satow T, Takagi T, Murao K, Miyamoto S, Iihara K. Efficacy and safety of single versus dual antiplatelet therapy for coiling of unruptured aneurysms. J Stroke Cerebrovasc Dis. 2013;22(5):650–655. doi:10.1016/j.jstrokecerebrovasdis.2012.02.008.

13 Lee SJ, Cho YD, Kang HS, Kim JE, Han MH. Coil embolization using the self-expandable closed-cell stent for intracranial saccular aneurysm: a single-center experience of 289 consecutive aneurysms. Clin Radiol. 2013;68(3):256–263. doi:10.1016/j.crad.2012.07.017.

14 Hwang G, Kim JG, Song KS, et al. Delayed ischemic stroke after stent-assisted coil placement in cerebral aneurysm: characteristics and optimal duration of preventative dual antiplatelet therapy. Radiology. 2014;273(1):194–201. doi:10.1148/radiol.14140070.

15 Hwang G, Huh W, Lee JS, et al. Standard vs Modified Antiplatelet Preparation for Preventing Thrombo- embolic Events in Patients With High On-Treatment Platelet Reactivity Undergoing Coil Embolization for an Unruptured Intracranial Aneurysm: A Randomized Clinical Trial. JAMA Neurol. 2015;72(7):764–772. doi:10.1001/jamaneurol.2015.0654.

16 Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013;382(9892):614–623. doi:10.1016/S0140-6736(13)61170-8.

17 Enomoto Y, Yoshimura S, Sakai N, Egashira Y,Japanese Registry of Neuroendovascular Therapy (JR-NET) investigators. Current perioperative management of anticoagulant and antiplatelet use in neuroendovascular therapy: analysis of JR-NET1 and 2. Neurol Med Chir (Tokyo). 2014;54 Suppl 2:9–16. doi:10.2176/nmc. oa2013-0160.

18 S K Swan, J V St Peter, L J Lambrecht, Hursting MJ. Comparison of Anticoagulant Effects and Safety of Argatroban and Heparin in Healthy Subjects. Pharmacotherapy. 2000;20(7):756–770. doi:10.1592/ phco.20.9.756.35194.

19 Klingele M, Enkel J, Speer T, Bomberg H , Baerens L , Schäfers HJ. Bleeding complications after cardiac surgery, before anticoagulantion start and then with argatroban or heparin in the early postoperative setting. J Cardiothorac Surg. 2020 ;15(1):27. doi:10.1186/s13019-020-1059-8.

20 Nishi H, Nakahara I, Matsumoto S, et al. Platelet reactiveity and hemorrhage risk in neurointerventional procedures under dual antiplatelet therapy. J NeuroInterv Surg. 2016;8(9):949–953. doi:10.1136/neurint- surg-2015-011844.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る